18 research outputs found
Demographics of subjects with successfully obtained HIV-1 <i>pol</i> sequences.
<p>Demographics of subjects with successfully obtained HIV-1 <i>pol</i> sequences.</p
Success probability of future regimen by the EuResist prediction engine.
<p>Prediction is based on drug resistance mutation profile and data on previous drug exposure, age, gender and CD4 at failure. Results are presented in ordered of increasing difference between a scenario where all approved NRTIs, NNRTIs and PIs are available versus currently available drugs in Tanzania. A) subjects failing first line therapy; B) subjects failing second line therapy (viral load included in prediction model).</p
Genotypic sensitivity scores for all reverse transcriptase and protease inhibitors.
<p>Percentage (%) of patient strains classified as susceptible, intermediate or resistant as per the Rega V.9.1.0 algorithm; first line failure (n = 43) and second line virological failure cases (n = 26) presented with separate paired bars (first line left bar, second line right bar).</p
Antiretroviral drug resistance mutations in Tanzanian subjects at first line clinico-immunological ART failure.
<p>A) stratified by treatment duration (n = 38); B) stratified by CD4 cells at failure (n = 36).</p
Univariate and Multivariate Cox proportional regression analysis to show the risk factors for developing DILI.
<p>Univariate and Multivariate Cox proportional regression analysis to show the risk factors for developing DILI.</p
Kaplan-Meier curves indicating estimate cumulative hazard for the development of drug induced liver injury between HIV patients receiving efavirenz based HAART alone and TB-HIV coinfected patients receiving efavirenz based HAART with rifampicin based anti-TB therapy during the first three months of follow up period.
<p>Kaplan-Meier curves indicating estimate cumulative hazard for the development of drug induced liver injury between HIV patients receiving efavirenz based HAART alone and TB-HIV coinfected patients receiving efavirenz based HAART with rifampicin based anti-TB therapy during the first three months of follow up period.</p
Description of demographic and baseline laboratory characteristics of patients with and without DILI.
<p>Description of demographic and baseline laboratory characteristics of patients with and without DILI.</p
Kaplan-Meier curves indicating estimate cumulative hazard for the development of drug induced liver injury between the different CYP2B6*6 genotypes in patients receiving efavirenz based HAART with or without rifampicin based anti-TB therapy during the first three months of follow up period.
<p>Kaplan-Meier curves indicating estimate cumulative hazard for the development of drug induced liver injury between the different CYP2B6*6 genotypes in patients receiving efavirenz based HAART with or without rifampicin based anti-TB therapy during the first three months of follow up period.</p
Comparison of mean log efavirenz plasma concentrations at week 4 and week 16 of efavirenz therapy between Ethiopian and Tanzanian HIV patients having the same <i>CYP2B6*6</i> genotype.
<p>Boxes indicate mean ± SE of the mean; bars indicate mean ±1.96 × SE of the mean.</p
Comparison of mean ± SE of mean efavirenz plasma concentration on the 4<sup>th</sup> and 16<sup>th</sup> weeks after initiation of efavirenz based HAART separately between Ethiopian and Tanzanian patients using independent t test.
<p>Comparison of efavirenz concentration between week 4 and week 16 with in Ethiopians and Tanzanian patients was done using paired t test. Boxes indicate mean ± SE of the mean; bars indicate mean ±1.96 × SE of the mean.</p